5,5-dimethyl-3-(4-nitroso-3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione

5,5-dimethyl-3-(4-nitroso-3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione, also known as NTI, is a potent and selective agonist for the α7 subtype of the nicotinic acetylcholine receptor (nAChR). The nAChR is a ligand-gated ion channel found in the brain and peripheral nervous system, and is involved in a variety of physiological processes including learning, memory, and pain modulation. NTI has been shown to improve cognitive function and reduce inflammation in animal models, making it a potential therapeutic agent for Alzheimer's disease and other neuroinflammatory disorders. Chemically, NTI is a heterocyclic compound containing an imidazolidine-2,4-dione ring system and a trifluoromethyl-substituted nitrosobenzene moiety. Its molecular formula is C14H12F3N3O3 and its molecular weight is 331.3 g/mol. NTI is highly soluble in organic solvents such as DMSO and ethanol, but is sparingly soluble in water. Despite its promising pharmacological properties, NTI has not yet been approved for clinical use due to concerns about its potential toxicity and adverse effects. Further research is needed to fully understand its safety and efficacy, as well as to develop more selective and potent α7 nAChR agonists with improved pharmacokinetic properties.